A Trial Investigating the Absorption, Metabolism and Excretion of Somapacitan After Single Dosing in Healthy Male Subjects

Phase 1 Completed 7 enrolled Novo Nordisk A/S

NaSingle-groupOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of the trial is to investigate the absorption, metabolism and excretion of somapacitan after single subcutaneous dosing in healthy male subjects.

Timeline

Start: 2016-11
Primary completion: 2017-01
Completion: 2017-01

Publications

Helleberg H, Bjelke M, Damholt BB, Pedersen PJ, Rasmussen MH. Absorption, metabolism and excretion of once-weekly somapacitan, a long-acting growth hormone derivative, after single subcutaneous dosing in human subjects. Eur J Pharm Sci. 2021 Dec 1;167:106030. doi: 10.1016/j.ejps.2021.106030. Epub 2021 Oct 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	somapacitan	Protein / enzyme biologic	6 mg	Subcutaneous

Indications

No indication recorded.